Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer

9 Jul 2020

Abstract excerpt

High grade serous ovarian cancer (HGSOC) is a fatal gynecologic malignancy in the U.S. with limited treatment options. New therapeutic strategies include targeting of the cell cycle checkpoints, e.g., ATR and CHK1. We recently reported a promising clinical activity of the CHK1 inhibitor (CHK1i) prexasertib monotherapy in BRCA wild-type (BRCAwt) HGSOC patients. In this study, biopsies of treated patients and cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32647134
DOI: 10.1038/s41388-020-1383-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancerPMID 32647134Read ↗

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP InhibitionSemantic proximity Read ↗

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancerSemantic proximity Read ↗

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancerSemantic proximity Read ↗

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer ModelsSemantic proximity Read ↗

Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS AmplificationSemantic proximity Read ↗

Chk1 Inhibitors for Novel Cancer TreatmentSemantic proximity Read ↗

Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancerSemantic proximity Read ↗

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in CancerSemantic proximity Read ↗

Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer modelsSemantic proximity Read ↗

Unleashing Chk1 in cancer therapySemantic proximity Read ↗

Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis groupSemantic proximity Read ↗

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing drugs in RB1-deficient ovarian and breast cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.